SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer

Zhiquan Huang, Haigang Li, Qi Huang, Dan Chen, Jingjing Han, Lili Wang, Chanbin Pan, Weiliang Chen, Michael House, Kenneth Nephew, Zhongmin Guo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Resistance to cisplatin-based chemotherapy is responsible for the majority of deaths from head and neck squamous cell carcinoma (HNSCC). In this study, using genome-wide gene expression analysis to investigate potential molecular mediators of HNSCC chemoresistance, we identified SERPINB2, a known inhibitor of extracellular serine proteinase urokinase-type plasminogen activator (uPA), as an important candidate. Whereas SERPINB2 is known to function as a suppressor of uPA molecular cascades, many of which play important roles in tumor invasion and metastasis, a role for SERPINB2 in cancer drug resistance has not been examined. By using quantitative real-time PCR and Western blot analysis, we determined that SERPINB2 mRNA and protein levels correlated with chemoresistance in HNSCC cell lines, and significantly lower SERPINB2 expression levels were observed in two cisplatin resistant HNSCC subclones compared to their isogenic drug-sensitive parental lines. Immunohistochemical analysis of HNSCC tumor tissues from patients treated with neoadjuvant cisplatin-based chemotherapy (n = 67 cases) revealed a significant association between SERPINB2 protein levels, tumor differentiation and patient relapse. Moreover, SERPINB2 down-regulation was a strong predictor of reduced overall survival in patients with HNSCC who received cisplatin-based chemotherapy (P = 0.001, log rank test). Studies using either siRNA-mediated down-regulation or forced over-expression of SERPINB2 in HNSCC cell lines confirmed a functional role for SERPINB2 in drug resistance. The findings were further supported using chemical inhibitors of STAT3 activity (a downstream effecter of uPAR signaling pathway), showing that STAT3 suppression altered HNSCC cell line cisplatin sensitivity. This is the first report on a role for SERPINB2 in acquired resistance to cisplatin in patients with HNSCC.

Original languageEnglish
Pages (from-to)777-786
Number of pages10
JournalMolecular Carcinogenesis
Volume53
Issue number10
DOIs
StatePublished - 2014

Fingerprint

Head and Neck Neoplasms
Down-Regulation
Cisplatin
Urokinase-Type Plasminogen Activator
Drug Resistance
Drug Therapy
Cell Line
Neoplasms
Carcinoma, squamous cell of head and neck
Serine Proteinase Inhibitors
Small Interfering RNA
Real-Time Polymerase Chain Reaction
Proteins
Western Blotting
Genome
Neoplasm Metastasis
Gene Expression
Recurrence
Messenger RNA
Survival

Keywords

  • Chemoresistance
  • Chemotherapy
  • Head and neck cancer
  • Serpin peptidase inhibitor B2(SERPINB2)
  • UPAR signaling

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology

Cite this

Huang, Z., Li, H., Huang, Q., Chen, D., Han, J., Wang, L., ... Guo, Z. (2014). SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer. Molecular Carcinogenesis, 53(10), 777-786. https://doi.org/10.1002/mc.22033

SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer. / Huang, Zhiquan; Li, Haigang; Huang, Qi; Chen, Dan; Han, Jingjing; Wang, Lili; Pan, Chanbin; Chen, Weiliang; House, Michael; Nephew, Kenneth; Guo, Zhongmin.

In: Molecular Carcinogenesis, Vol. 53, No. 10, 2014, p. 777-786.

Research output: Contribution to journalArticle

Huang, Z, Li, H, Huang, Q, Chen, D, Han, J, Wang, L, Pan, C, Chen, W, House, M, Nephew, K & Guo, Z 2014, 'SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer', Molecular Carcinogenesis, vol. 53, no. 10, pp. 777-786. https://doi.org/10.1002/mc.22033
Huang, Zhiquan ; Li, Haigang ; Huang, Qi ; Chen, Dan ; Han, Jingjing ; Wang, Lili ; Pan, Chanbin ; Chen, Weiliang ; House, Michael ; Nephew, Kenneth ; Guo, Zhongmin. / SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer. In: Molecular Carcinogenesis. 2014 ; Vol. 53, No. 10. pp. 777-786.
@article{87d0d1d2fc444455a9345b406087643e,
title = "SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer",
abstract = "Resistance to cisplatin-based chemotherapy is responsible for the majority of deaths from head and neck squamous cell carcinoma (HNSCC). In this study, using genome-wide gene expression analysis to investigate potential molecular mediators of HNSCC chemoresistance, we identified SERPINB2, a known inhibitor of extracellular serine proteinase urokinase-type plasminogen activator (uPA), as an important candidate. Whereas SERPINB2 is known to function as a suppressor of uPA molecular cascades, many of which play important roles in tumor invasion and metastasis, a role for SERPINB2 in cancer drug resistance has not been examined. By using quantitative real-time PCR and Western blot analysis, we determined that SERPINB2 mRNA and protein levels correlated with chemoresistance in HNSCC cell lines, and significantly lower SERPINB2 expression levels were observed in two cisplatin resistant HNSCC subclones compared to their isogenic drug-sensitive parental lines. Immunohistochemical analysis of HNSCC tumor tissues from patients treated with neoadjuvant cisplatin-based chemotherapy (n = 67 cases) revealed a significant association between SERPINB2 protein levels, tumor differentiation and patient relapse. Moreover, SERPINB2 down-regulation was a strong predictor of reduced overall survival in patients with HNSCC who received cisplatin-based chemotherapy (P = 0.001, log rank test). Studies using either siRNA-mediated down-regulation or forced over-expression of SERPINB2 in HNSCC cell lines confirmed a functional role for SERPINB2 in drug resistance. The findings were further supported using chemical inhibitors of STAT3 activity (a downstream effecter of uPAR signaling pathway), showing that STAT3 suppression altered HNSCC cell line cisplatin sensitivity. This is the first report on a role for SERPINB2 in acquired resistance to cisplatin in patients with HNSCC.",
keywords = "Chemoresistance, Chemotherapy, Head and neck cancer, Serpin peptidase inhibitor B2(SERPINB2), UPAR signaling",
author = "Zhiquan Huang and Haigang Li and Qi Huang and Dan Chen and Jingjing Han and Lili Wang and Chanbin Pan and Weiliang Chen and Michael House and Kenneth Nephew and Zhongmin Guo",
year = "2014",
doi = "10.1002/mc.22033",
language = "English",
volume = "53",
pages = "777--786",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer

AU - Huang, Zhiquan

AU - Li, Haigang

AU - Huang, Qi

AU - Chen, Dan

AU - Han, Jingjing

AU - Wang, Lili

AU - Pan, Chanbin

AU - Chen, Weiliang

AU - House, Michael

AU - Nephew, Kenneth

AU - Guo, Zhongmin

PY - 2014

Y1 - 2014

N2 - Resistance to cisplatin-based chemotherapy is responsible for the majority of deaths from head and neck squamous cell carcinoma (HNSCC). In this study, using genome-wide gene expression analysis to investigate potential molecular mediators of HNSCC chemoresistance, we identified SERPINB2, a known inhibitor of extracellular serine proteinase urokinase-type plasminogen activator (uPA), as an important candidate. Whereas SERPINB2 is known to function as a suppressor of uPA molecular cascades, many of which play important roles in tumor invasion and metastasis, a role for SERPINB2 in cancer drug resistance has not been examined. By using quantitative real-time PCR and Western blot analysis, we determined that SERPINB2 mRNA and protein levels correlated with chemoresistance in HNSCC cell lines, and significantly lower SERPINB2 expression levels were observed in two cisplatin resistant HNSCC subclones compared to their isogenic drug-sensitive parental lines. Immunohistochemical analysis of HNSCC tumor tissues from patients treated with neoadjuvant cisplatin-based chemotherapy (n = 67 cases) revealed a significant association between SERPINB2 protein levels, tumor differentiation and patient relapse. Moreover, SERPINB2 down-regulation was a strong predictor of reduced overall survival in patients with HNSCC who received cisplatin-based chemotherapy (P = 0.001, log rank test). Studies using either siRNA-mediated down-regulation or forced over-expression of SERPINB2 in HNSCC cell lines confirmed a functional role for SERPINB2 in drug resistance. The findings were further supported using chemical inhibitors of STAT3 activity (a downstream effecter of uPAR signaling pathway), showing that STAT3 suppression altered HNSCC cell line cisplatin sensitivity. This is the first report on a role for SERPINB2 in acquired resistance to cisplatin in patients with HNSCC.

AB - Resistance to cisplatin-based chemotherapy is responsible for the majority of deaths from head and neck squamous cell carcinoma (HNSCC). In this study, using genome-wide gene expression analysis to investigate potential molecular mediators of HNSCC chemoresistance, we identified SERPINB2, a known inhibitor of extracellular serine proteinase urokinase-type plasminogen activator (uPA), as an important candidate. Whereas SERPINB2 is known to function as a suppressor of uPA molecular cascades, many of which play important roles in tumor invasion and metastasis, a role for SERPINB2 in cancer drug resistance has not been examined. By using quantitative real-time PCR and Western blot analysis, we determined that SERPINB2 mRNA and protein levels correlated with chemoresistance in HNSCC cell lines, and significantly lower SERPINB2 expression levels were observed in two cisplatin resistant HNSCC subclones compared to their isogenic drug-sensitive parental lines. Immunohistochemical analysis of HNSCC tumor tissues from patients treated with neoadjuvant cisplatin-based chemotherapy (n = 67 cases) revealed a significant association between SERPINB2 protein levels, tumor differentiation and patient relapse. Moreover, SERPINB2 down-regulation was a strong predictor of reduced overall survival in patients with HNSCC who received cisplatin-based chemotherapy (P = 0.001, log rank test). Studies using either siRNA-mediated down-regulation or forced over-expression of SERPINB2 in HNSCC cell lines confirmed a functional role for SERPINB2 in drug resistance. The findings were further supported using chemical inhibitors of STAT3 activity (a downstream effecter of uPAR signaling pathway), showing that STAT3 suppression altered HNSCC cell line cisplatin sensitivity. This is the first report on a role for SERPINB2 in acquired resistance to cisplatin in patients with HNSCC.

KW - Chemoresistance

KW - Chemotherapy

KW - Head and neck cancer

KW - Serpin peptidase inhibitor B2(SERPINB2)

KW - UPAR signaling

UR - http://www.scopus.com/inward/record.url?scp=84908346880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908346880&partnerID=8YFLogxK

U2 - 10.1002/mc.22033

DO - 10.1002/mc.22033

M3 - Article

C2 - 23661500

AN - SCOPUS:84908346880

VL - 53

SP - 777

EP - 786

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 10

ER -